FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, and concerns pharmaceutical compositions able to induce cancer cell apoptosis for diagnosing and treating B-cell chronic lymphocytic leukaemia. Substance of the inventions involves the pharmaceutical compositions for treating B-cell chronic lymphocytic leukaemia containing an active ingredient presented by a humanised monoclonal antibody T1h from a secreting hybridoma IOR-TIA under depositary No. ECACC 96112640, identifying a leukocyte differentiation antigen CD6. A diagnostic reagent also contains said antibody.
EFFECT: advantage of the group of inventions consists in higher specific activity.
11 cl, 4 ex, 4 dwg
| Title |
Year |
Author |
Number |
| PHARMACEUTICAL COMPOSITION CONTAINING AHTM-CD6 MONOCLONAL ANTIBODY, APPLICABLE FOR DIAGNOSING AND TREATING RHEUMATOID ARTHRITIS |
2007 |
- Montero Kasimiro Khose Ehnrike
- Kasako Parada Ankhel' Rajmundo
- Masorra Ehrrera Saima
- Alonso Ramires Rubi
- Peres Rodriges Rolando
|
RU2472526C2 |
| ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT |
2006 |
- Mun'Os Kall'Ekha Sesilija
- Al'Fonso Peres Manuehl' Khesus
- Lopes Khiral' Sonia
|
RU2404808C2 |
| ANTIBODIES TO CD6 FOR THE TREATMENT OF SEVERE ASTHMA |
2019 |
- Konnelli, Stiven
- Ng, Sheri
|
RU2796586C2 |
| TREATMENT OF B-CELLULAR MALIGNANT TUMORS USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR BY CHEMOTHERAPY AND RADIOTHERAPY |
2000 |
- Khanna Nabil
- Kharikharan Kandasami
|
RU2305561C2 |
| DECREASING B-CELL COUNT WITH USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES |
2006 |
- Grosmehjr Laura S'Ju
- Khajdehn-Ledbehttehr Marta S'Juzan
- Ledbehttehr Dzheffri A.
- Tompson Piter Armstrong
- Sajmon Sandi Aleksander
- Brehdi Uill'Jam
|
RU2423381C2 |
| OLIGONUCLEOTIDES OR THEIR FUNCTIONAL HOMOLOGUES, COMPOSITION CONTAINING THEM AND METHOD OF TREATING B-CELL TUMOUR |
2006 |
- Van Li-In
- Bao Mu-Shehn
- Juj Jun-Li
|
RU2413519C2 |
| OLIGONUCLEOTIDE OR ITS FUNCTIONAL HOMOLOG, COMPOSITION CONTAINING IT AND METHOD OF TREATING OF B-LYMPHOID NEOPLASM |
2006 |
- Van Li-In
- Bao Mu-Shehn
- Juj Jun-Li
|
RU2409672C2 |
| SPECIFIC ANTIBODY TO S100A4 OR ITS FRAGMENT (VERSIONS), METHOD OF PRODUCTION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS, HYBRIDOMA CELL LINE (VERSIONS), CONJUGATE, COMPOSITION, METHOD OF PREVENTING AND/OR TREATING CANCER, METASTASIS, ANGIOGENESIS AND INFLAMMATORY DISEASES, METHOD AND KIT FOR DIAGNOSING CANCER OR DISEASE ASSOCIATED WITH INFLAMMATION (VERSIONS), METHOD OF DETECTING S100A4, METHOD OF MAKING INDIVIDUAL THERAPY |
2011 |
- Adan Plana Khaume
- Barbera Ferrando Laura
- Gomes Kasakhus Luis Ankhel
- Dakel Plasa Sejla
- Kalvis Kalpe Karme
- Kol Mansano Antonio
- Martines Eskola Khosep Mariya
- Masa Alvares Mark
- Mitkhans Prat Fransesk
- Messeger Pejpoch Ramon
- Padilya Garsiya Laura
- Rivas Kanyas Manuel
- Roke Navarro Lurdes Tatyana
- Ervas Vilegas Rosa Ma
- Ernandes Miges Khose Luis
|
RU2615684C2 |
| COMBINED THERAPY BY AFUCOSYLATED ANTIBODY FOR CD20 WITH ANTIBODY FOR VEGF |
2011 |
- Gerting Frank
- Klyajn Kristian
|
RU2615459C2 |
| USING PURINE DERIVATIVES FOR PREPARING DRUG PREPARATION |
2008 |
- Mezhe Loran
- Bettajeb Karima
- Galon Ehrve
- Umata Nassima
- Bertu Kristian
- Lester Karin
|
RU2500400C2 |
